Aditxt Inc (OQ:ADTX)

Business Focus: Bio Therapeutic Drugs

Mar 27, 2024 08:36 am ET
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth --
Feb 01, 2024 07:00 am ET
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth 
Jan 30, 2024 08:30 am ET
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced the acquisition of a portfolio of EEG brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. (“Brain Scientific”). The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care.
Jan 08, 2024 08:30 am ET
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximatel
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. (“Pearsanta”), has acquired MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. The portfolio of assets to be acquired includes the pioneering Mitomic™ technology that harnesses the uni
Jan 05, 2024 08:30 am ET
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrants in lieu thereof) and accompanying warrants, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is b
Jan 02, 2024 08:30 am ET
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1), subject to a mandatory panel monitor until December 29, 2024.
Dec 29, 2023 05:07 pm ET
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof
Dec 18, 2023 12:57 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM),
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 14, 2023 01:23 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ADTX, EVFM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Codorus Valley Bancorp, Inc. (NASDAQ:...
Dec 12, 2023 09:53 am ET
ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aditxt, Inc. (NASDAQ: ADTX) and Evofem Biosciences, Inc. is fair to Aditxt shareholders.
Dec 12, 2023 08:30 am ET
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive H
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women’s health, today announced the signing of a definitive agreement (the “Agreement”) under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million (the “Transaction”). Pending a successful Transaction, it wi
Nov 30, 2023 08:31 am ET
Thinking about buying stock in Aditxt Inc, Ampio Pharmaceuticals, TOP SHIPS, Mullen Automotive, or Oatly Group ?
NEW YORK, Nov. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADTX, AMPE, TOPS, MULN, and OTLY.
Oct 06, 2023 08:00 am ET
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt” or the "Company"), an innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system will present at the 8th Annual Dawson James...
Oct 05, 2023 08:00 am ET
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, I
Sep 21, 2023 09:35 am ET
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand...
Sep 08, 2023 07:05 am ET
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being h
Sep 06, 2023 04:30 pm ET
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) and accompanying warrant, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is
Aug 31, 2023 07:00 pm ET
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof
Aug 18, 2023 07:02 am ET
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives.
Aug 17, 2023 04:12 pm ET
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock (instead of Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. East
Aug 17, 2023 12:00 pm ET
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on August 18, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on August 18, 2023, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the annual meeting held on August 16, 2023,
Jun 20, 2023 07:49 am ET
Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Na
Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an exclusive non-binding Letter of Intent (“LOI”) by Pearsanta,™ Inc. (“Pearsanta”), a wholly-owned subsidiary of
May 05, 2023 07:05 am ET
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that modulate and monitor the immune system, today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune dis
Apr 24, 2023 04:15 pm ET
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.22 per share (or common stock equivalents in lieu thereof) priced at-the-market under Nasdaq rules. In a concurrent private pl
Apr 20, 2023 01:35 pm ET
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.22 per share (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurren
Apr 20, 2023 08:00 am ET
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. (”Cellvera”) that grants Aditxt (whether directly or in its recen
Apr 17, 2023 07:00 am ET
Aditxt Issues Shareholder Update
Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its three innovation programs and strategic M&A initiatives.
Mar 08, 2023 08:30 am ET
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased to announce Maureen Connolly has joined Aditxt as Chief Content and Engagement Officer. Connolly is an award-winning content strategist and audience builder wi
Mar 03, 2023 08:30 am ET
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has retained Riverside Management Group, LLC (“Riverside Management Group” or “RMG”), a merchant banking firm providing investment banking advisory ser
Feb 14, 2023 08:30 am ET
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve a
Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. (“Pearsanta”), to accelerate the growth of Aditxt’s second program, AditxtScore™,
Jan 03, 2023 09:00 am ET
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, a
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. (“Adimune™) and its plans towards submission of a Clinical Trial Application (“CTA”) for its
Oct 21, 2022 09:00 am ET
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human
Oct 12, 2022 09:00 am ET
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed rese
Oct 07, 2022 09:00 am ET
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
Aditxt, Inc.’s (NASDAQ: ADTX) (“Aditxt”, or the “Company”) AditxtScore™ is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19.
Sep 29, 2022 09:00 am ET
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel (“Nasdaq”) that it has regained compliance with the minimum bid price re
Sep 29, 2022 08:32 am ET
Thinking about buying stock in Axcella Health, Century Aluminum, Senti Biosciences, Camber Energy, or Aditxt?
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXLA, CENX, SNTI, CEI, and ADTX.
Sep 27, 2022 09:00 am ET
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today provides shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering.
Sep 26, 2022 10:55 am ET
Thinking about buying stock in Aditxt, RedHill Biopharma, Corbus Pharmaceuticals, Li Auto, or Kiora Pharmaceuticals?
NEW YORK, Sept. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADTX, RDHL, CRBP, LI, and KPRX.
Sep 20, 2022 04:09 pm ET
Aditxt Announces Closing of $20.0 Million Public Offering
Aditxt, Inc., (Nasdaq: ADTX) (the “Company” or “Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the closing of its previously announced public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (or common stock equivalent) and associated warrant. The warrants have an exercise price of $6.00 per share, are e
Sep 16, 2022 09:31 am ET
Thinking about buying stock in Revance Therapeutics, Uber Technologies, Roblox, Aditxt, or Roku?
NEW YORK, Sept. 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RVNC, UBER, RBLX, ADTX, and ROKU.
Sep 16, 2022 09:20 am ET
Aditxt Announces Pricing of $20.0 Million Public Offering
Aditxt, Inc., (Nasdaq: ADTX) (the “Company” or “Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the pricing of a public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (or common stock equivalent) and associated warrants. The warrants will have an exercise price of $6.00 per share, are exercisable immedi
Sep 15, 2022 09:31 am ET
Thinking about buying stock in Store Capital, AMTD Idea Group, Phunware, Fusion Pharmaceuticals, or Aditxt?
NEW YORK, Sept. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STOR, AMTD, PHUN, FUSN, and ADTX.
Sep 14, 2022 08:30 am ET
Thinking about buying stock in Aditxt, Scisparc, Akerna, InMed Pharmaceuticals, or Eos Energy?
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADTX, SPRC, KERN, INM, and EOSE.
Sep 13, 2022 04:15 pm ET
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on September 14, 2022, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the special meeting held on September 7, 2022, wit
Sep 12, 2022 08:30 am ET
Thinking about buying stock in Ventyx Biosciences, Aterian, Aditxt, RA Medical Systems, or Spectrum Pharmaceuticals?
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTYX, ATER, ADTX, RMED, and SPPI.
Aug 02, 2022 08:17 am ET
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc.
via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part...
Jul 11, 2022 11:25 am ET
Thinking about buying stock in Mullen Automotive, Iterum Therapeutics, Endo International, Aditxt, or COMSovereign?
NEW YORK, July 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, ITRM, ENDP, ADTX, and COMS.
Jul 08, 2022 08:30 am ET
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immu
Jun 14, 2022 02:00 pm ET
Premier Medical Laboratory Services Now Offering AditxtScore™ Personalized Immune Test for COVID-19
GREENVILLE, S.C., June 14, 2022 /PRNewswire/ -- Premier Medical Laboratory Services (PMLS), a nation leading advanced medical diagnostics lab, adds AditxtScore™ to its menu of testing services. Providing more clarity regarding a patient's individual immunity profile, AditxtScore™ allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. Now that a large segment of the population has either undergone vaccination or experienced a symptomatic or asymptomatic infection with SARS-CoV-2, AditxtScoreä provides information on immune stat
May 05, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADTX, RCM, EXTN, ZWS
NEW YORK, May 5, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 04, 2022 05:44 pm ET
ADITXT INVESTOR ALERT - Kuznicki Law PLLC Investigates Aditxt, Inc. - ADTX
Kuznicki Law PLLC is investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000. Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 39.9 million shares of common stock of Aditxt and a cash payment
Apr 14, 2022 09:00 am ET
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth
Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC (“Guthy-Renker”). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work with GRS to produce and subsequently air AditxtScore™ TV commercials in order to help set the stage for an i
Apr 05, 2022 08:30 am ET
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th
Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC (“Cellvera”), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separate agreement to extend the term of the previously announced loan and forbearance agreements. Cellvera holds exclusive worldwide rig
Mar 23, 2022 08:30 am ET
Aditxt to Participate in the 2022 Virtual Growth Conference
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
Mar 15, 2022 09:00 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates AMCI, EDNC, PAQC, ADTX
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AMCI Acquisition Corp. II (NASDAQ:...
Mar 10, 2022 05:28 pm ET
ADITXT INVESTOR ALERT - Kuznicki Law PLLC Investigates Adequacy of Price and Process in Proposed Sale of Aditxt, Inc. - ADTX
Kuznicki Law PLLC is investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000. Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 39.9 million shares of common stock of Aditxt and a cash payment
Mar 07, 2022 08:30 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, SKIL, OCDX, ADTX, MIME
NEW YORK, March 7, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 02, 2022 06:07 pm ET
ADITXT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Aditxt, Inc. - ADTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000. Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange f
Jan 18, 2022 08:30 am ET
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including
Aditxt, Inc. (“Aditxt,” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to advance humanity’s transition to the “Age of Immunity,” has submitted two EUA applications for AditxtScore™ for COVID-19. This lab-developed blood test provides a more comprehensive profile of the body’s immune response to COVID-19.
Jan 15, 2022 01:02 pm ET
Halper Sadeh LLP Investigates FLMN, VCRA, ADTX, OCDX; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Falcon Minerals Corporation (NASDAQ: FLMN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jan 14, 2022 09:00 am ET
Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.
Jan 12, 2022 09:00 am ET
Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.
Jan 11, 2022 02:25 pm ET
Halper Sadeh LLP Investigates EPAY, VRS, HXOH, OCDX, ADTX; Shareholders are Encouraged to Contact the Firm
NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 10, 2022 01:01 pm ET
Shareholder Alert: The M&A Class Action Firm Announces an Investigation of the Merger
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 05, 2022 11:01 am ET
Halper Sadeh LLP Investigates TMX, SKIL, LAWS, ADTX; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Terminix Global Holdings, Inc. (NYSE: TMX) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jan 04, 2022 08:57 pm ET
ADITXT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Aditxt, Inc. - ADTX
NEW ORLEANS, Jan. 4, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. ("the Company") (NasdaqCM: ADTX).  Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000. Aditxt would then acquire the remaining 90.5% of the issued and outst
Jan 04, 2022 01:12 pm ET
ADITXT ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ADTX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Aditxt, Inc. (NASDAQ: ADTX) breached their fiduciary duties or violated the federal securities...
Jan 04, 2022 11:43 am ET
Moore Kuehn Encourages ADTX, LAWS, SKIL, and GPCO Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek...
Jan 04, 2022 05:20 am ET
Halper Sadeh LLP Investigates LAWS, ADTX, SKIL, VRS, BRG; Shareholders are Encouraged to Contact the Firm
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 03, 2022 12:01 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Aditxt, Inc. Merger
Rigrodsky Law, P.A. announces that it is investigating Aditxt, Inc. (“Aditxt”) (NASDAQ CM: ADTX) regarding possible breaches of fiduciary duties and other violations of law related to Aditxt’s agreement to acquire AiPharma Global Holdings LLC...
Dec 30, 2021 03:58 pm ET
Halper Sadeh LLP Investigates LAWS, ADTX, EPAY, SKIL, HXOH; Shareholders are Encouraged to Contact the Firm
NEW YORK, Dec. 30, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 29, 2021 08:45 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Aditxt, Inc.
NEW YORK, Dec. 29, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), in connection with the proposed merger of the Company with AiPharma Global Holdings LLC ("AiPharma").  Under the terms of the share exchange agreement, the Company will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000.  Aditxt
Dec 29, 2021 09:06 am ET
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore™
Dec 28, 2021 12:33 pm ET
Aditxt (ADTX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Aditxt Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADTX
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Aditxt Inc. (NASDAQ: ADTX) and AiPharma Global Holdings LLC is fair to Aditxt shareholders.
Dec 28, 2021 09:00 am ET
Aditxt Signs Share Exchange Agreement to Acquire AiPharma
Aditxt Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, has signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly-owned subsidiary of AiPharma Group Ltd. (“AiPharma”). The share exchange agreement contemplates that the transaction would involve two steps. First, an initial closing is expected to occur upon the satisfaction of certain conditions no later than January 31, 2022, at which Aditxt will acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approx
Dec 28, 2021 08:31 am ET
Thinking about buying stock in Energy Focus, 9 Meters Biopharma, Aditxt, ReTo Eco-Solutions, or Aeva Technologies?
NEW YORK, Dec. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, NMTR, ADTX, RETO, and AEVA.
Dec 13, 2021 08:44 am ET
Aditxt, Inc. Signs Non-Binding Letter of Intent to Acquire Point-of-Care Diagnostic Technology Development Company
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed a non-binding letter of intent (“LOI”) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 (COVID-
Dec 06, 2021 05:56 pm ET
Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants
Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 16,575,000 units, consisting of shares of its common stock and warrants to purchase up to 16,575,000 shares of its common stock at a public offering price of $1.05 per unit, for aggregate gross proceeds of $17,403,750, prior to deducting underwriter discounts, commissions, and other offering expenses. Units were not issued or certificated. The shares of common sto
Dec 02, 2021 09:20 am ET
Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into an amendment to its previously announced transaction agreement with AiPharma Global extending the outside date by which the parties have to execute a definitive agreemen
Dec 01, 2021 09:36 am ET
Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor
Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the pricing of an underwritten public offering of 16,575,000 units, consisting of shares of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase up to 16,575,000 shares of its common stock at a public offering price of $1.05 per unit, for aggregate gross proceeds of $17,403,750, prior to deducting underwriter discounts, commissions, and other offering expenses. Units will not be issued or certifi
Nov 30, 2021 07:14 pm ET
Aditxt Announces Proposed Public Offering of Common Stock and Warrants
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the launch of an underwritten public offering.
Nov 22, 2021 09:00 am ET
The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Respond
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company that improves the health of the immune system, announced today that the Johnson County Sherriff’s Office, the largest law enforcement agency in the State of Kansas with over 700 employees, will become the first agency in the Nation to deploy AditxtScore™ for assessing
Nov 12, 2021 12:00 pm ET
Aditxt Webinar at 2pm ET to Explore PRESECO Results
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), has announced a webinar at 2pm ET this afternoon to discuss its earlier announcement today.
Nov 12, 2021 09:45 am ET
Thinking about buying stock in Altamira Therapeutics, FuelCell Energy, Doximity, Aditxt, or ChargePoint?
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CYTO, FCEL, DOCS, ADTX, and CHPT.
Nov 12, 2021 08:45 am ET
Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that the global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating oral Avigan®/Reeqonus™ (favipiravir) as a potential at-home therapy for patients w
Nov 03, 2021 09:00 am ET
Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform
Aditxt, Inc. (Nasdaq: ADTX), (“Aditxt” or the “Company”) a biotechnology innovation company with a mission to improve the health of the immune system, announced today a partnership with
Oct 20, 2021 05:31 pm ET
Aditxt Announces Closing of $4.25 Million Public Offering
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses.
Oct 20, 2021 08:00 am ET
Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the Company’s Co-Founder, Chairman, and CEO Amro Albanna will present at the
Oct 18, 2021 07:38 am ET
Aditxt Announces Pricing of $4.25 Million Public Offering
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the pricing of an underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses.
Oct 07, 2021 09:15 am ET
Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the Company’s Co-Founder, Chairman, and CEO Amro Albanna will present at the LD Micro Main Event in person on October 13, 2021 at 8:30 AM PT / 11:30 AM ET on Track 1. Mr. Albanna will also participa
Oct 06, 2021 08:30 am ET
Thinking about buying stock in Voyager Therapeutics, Aditxt, Agrify, Progenity, or Amplify Energy?
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYGR, ADTX, AGFY, PROG, and AMPY.
Oct 05, 2021 12:41 pm ET
AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since
DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement to sell all of its assets through the sale of one of its wholly owned group subsidaries, to Aditxt Inc. (Nasdaq: ADTX). Aditxt is a biotech innovation company with a mission to improve the health of the immune system.
Oct 05, 2021 10:40 am ET
Thinking about buying stock in Farmmi, Aditxt, Ring Energy, U.S. Energy, or Lordstown Motors?
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, ADTX, REI, USEG, and RIDE.
Oct 05, 2021 08:45 am ET
Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Can
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has entered into a transaction agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary (“AiPharma”) of AiPharma Global Holdings LLC (“AiPharma Global”) which is to own all of the assets of AiPharma Global, a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases.
Sep 27, 2021 09:31 am ET
Thinking about buying stock in Syndax Pharmaceuticals, Tellurian, RA Medical Systems, AST SpaceMobile, or Aditxt?
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDX, TELL, RMED, ASTS, and ADTX.
Sep 27, 2021 08:45 am ET
Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization
Aditxt, Inc. (“Aditxt, or the “Company”). (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been app
Sep 09, 2021 08:26 am ET
Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with SphereDX, an advanced clinical diagnostic lab focusing on next-generation genomic and metabolomic clinical testing, to offer its AditxtScore™ for COVID-19. The AditxtScore for COVID-19 is a more c
Sep 07, 2021 09:15 am ET
Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has closed on a registered direct offering for $11 million announced on August 26, 2021 and funded a bridge loan to its acquisition target, satisfying a key term of the Letter of Intent (LOI). Additionally, the Company entered into an agreement with the holder of its outstanding convertible note, whereby the parties agreed to waive certain rights with respect to the convertible note and modify certain provisions of the warrants held by the holder, and pursuant
Aug 26, 2021 10:45 am ET
Thinking about buying stock in Naked Brand, Aditxt, Support.com, Palantir Technologies, or Sundial Growers?
NEW YORK, Aug. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, ADTX, SPRT, PLTR, and SNDL.
Aug 26, 2021 09:15 am ET
Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into definitive agreements with certain institutional investors to purchase 4,583,334 shares of its common stock at a purchase price of $2.40 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $11.0 million, before payment of commissions and expenses. In a concurrent private placement, for each share of common stock purchased by an investor, such investor will receive from the
Aug 25, 2021 10:40 am ET
Thinking about buying stock in Sundial Growers, Naked Brand, New Oriental Education, Aditxt, or Sesen Bio?
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, NAKD, EDU, ADTX, and SESN.
Aug 25, 2021 09:16 am ET
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that it has signed a letter of intent ("the LOI") to acquire a biopharmaceutical company, the “Target Company”, commercializing COVID-19 antiviral oral therapy. The Target Company is currently selling its products under emerge
Aug 11, 2021 08:00 am ET
Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with Great Lakes Medical Laboratory, Inc. (GLML), a full-service medical reference laboratory, to offer its AditxtScore™ for COVID-19 throughout the State of Michigan. The AditxtScore for COVID-19 is a more compr
Aug 04, 2021 08:00 am ET
Aditxt Provides Update on AditxtReprogramming’s™ Apoptotic DNA Immunotherapy Therapeutic Platform
Aditxt, Inc. (the “Company” or “Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced its Psoriasis clinical program will now be slated for 2022 instead of December 2021 as previously announced. The updated timeline is due to a lengthier large scale clinical grade manufacturing and a
Jul 27, 2021 08:30 am ET
Thinking about buying stock in Eyegate Pharmaceuticals, Mogu, Aditxt, Powerbridge Technologies, or Cerecor?
NEW YORK, July 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EYEG, MOGU, ADTX, PBTS, and CERC.
Jul 12, 2021 08:00 am ET
Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced enhancements to its AditxtScore™ for COVID-19. A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been e
Jul 07, 2021 08:00 am ET
Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced the opening of its AditxtScore™ Center in Richmond, VA. This high-capacity, CLIA-validated immune monitoring center will be scalable to process several million complex immune system reports per year.
Jun 18, 2021 08:00 am ET
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
Jun 15, 2021 08:00 am ET
Aditxt Set to Join Russell Microcap® Index
MOUNTAIN VIEW, Calif., June 15, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that it is set to join the Russell Microcap® Index, effective after the US market opens on June 28, 2021.
Apr 01, 2021 07:30 am ET
Collection Sites, LLC Named AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring Through Its Mobile Testing Centres
Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) today announced that its wholly owned subsidiary, Collection Sites, LLC will offer AditxtScore™ for COVID-19 through its mobile testing centres. Aditx Therapeutics (Nasdaq: ADTX), is a...
Mar 22, 2021 08:31 am ET
Aditxt Announces Participation in the Benzinga Biotech Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - March 22, 2021) - Aditxt (NASDAQ: ADTX) will be presenting at the Benzinga Biotech Small Cap Conference taking place on March 24-25, 2021. We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.
Mar 04, 2021 08:30 am ET
Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Eazy Testing Inc. will be offering AditxtScore™ for...
Jan 29, 2021 09:24 am ET
Immunologist and Clinical Transplant Expert, Dolly B. Tyan, PhD, Joins Aditxt as Senior VP of Clinical Development - Transplantation
via NewMediaWire-- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and...
Jan 26, 2021 08:54 am ET
Aditxt Secures $5 Million Financing to Scale AditxtScore™ Operational Capacity
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Jan 21, 2021 08:00 am ET
AditxtScore™ Immune Monitoring Service Will be Operational on February 1st
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Dec 14, 2020 08:00 am ET
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Dec 08, 2020 08:00 am ET
Aditxt to Present at the 13th Annual LD Micro Main Event Conference
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Nov 30, 2020 08:30 am ET
Physician and Media Personality Dr. Drew and Aditxt CEO to Reveal and Discuss Their Personal AditxtScore™ for COVID-19 Results During AditxtEngage™ Live Event on Tuesday, December 1st at 10:00 am ET
via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Nov 20, 2020 08:00 am ET
Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore™
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Nov 19, 2020 08:30 am ET
Aditxt Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test (LDT)
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Nov 13, 2020 08:00 am ET
Aditxt Provides Business Update and Files Third Quarter 2020 10-Q
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Oct 02, 2020 04:05 pm ET
Aditxt Announces First AditxtEngage™ Event, Continuing Series of Investor Opportunities to Engage with Company
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Oct 01, 2020 08:00 am ET
Former Chief Medical Officer and Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security, Dr. Jeffrey Runge, Appointed to Aditxt Board of Directors
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Sep 10, 2020 04:30 pm ET
Aditx Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and reprogramming, today...
Sep 10, 2020 09:43 am ET
Aditx Therapeutics Announces Closing of Upsized $9.6 Million Follow-On Public Offering
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Sep 10, 2020 08:51 am ET
Physician and Media Personality Dr. Drew Pinsky, Dr. Drew, Joins Aditx Therapeutics as Senior Advisor to AditxtScore™ for Scoring the Immune System
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Sep 03, 2020 09:00 am ET
Aditxt Signs Collaboration Agreement with Salveo Diagnostics to Commercialize AditxtScore™ Platform Starting in Q4, 2020
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and reprogramming, today...
Sep 02, 2020 08:30 am ET
Aditx Therapeutics Announces Pricing of $9.6 Million Follow-On Public Offering
via NEWMEDIAWIRE ‒ Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 27, 2020 08:30 am ET
Aditx Therapeutics to Present at The LD 500 Virtual Conference
Presentation on Thursday, September 3rd at 12:20 PM ET
Aug 25, 2020 08:00 am ET
Head of R&D for the New Analyte Ventures at Abbott Diabetes Care, Namvar Kiaie Joins Aditx Therapeutics’ Board of Directors
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Aug 24, 2020 08:30 am ET
Aditxt Submits Emergency Use Authorization (EUA) Application for AditxtScore™ for COVID-19
via NEWMEDIAWIRE ‒ Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and reprogramming, today...
Aug 14, 2020 08:00 am ET
Former President of the Global Business Unit at Schering AG, Dr. Joachim-Friedrich Kapp, MD, PhD, to Lead Aditx Therapeutics Clinical Development, Autoimmunity
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Aug 06, 2020 08:00 am ET
Aditxt Introduces AditxtScore™ for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center
via NEWMEDIAWIRE -- Aditxt Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming, today...
Aug 03, 2020 08:00 am ET
Aditx Therapeutics Appoints Jeff Ramson, Wall Street Veteran and Founder of PCG Advisory as Senior Advisor, Capital Markets & Communications
via NEWMEDIAWIRE – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Jul 24, 2020 08:00 am ET
Founding Partner of Securities Law Firm Anthony L.G., Laura Anthony, Appointed to Aditx Therapeutics’ Board of Directors and Will Chair Its Governance Committee
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Jul 22, 2020 08:00 am ET
Aditxt to Present at Zooming with LD
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditx) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Jul 21, 2020 08:00 am ET
Former CFO of BlackRock Capital Investment Corporation and AIG Capital Partners' Global Emerging Markets Group Corinne Pankovcin, Joins Aditx Therapeutics as Chief Financial Officer
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Jul 16, 2020 11:00 am ET
'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st
LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.
Jul 10, 2020 08:00 am ET
CEO, CIO, and Senior Advisors of Aditxt Complete Conversion of ~$1.1 Million in Accrued Compensation into Restricted IPO Units
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming,...
Jul 06, 2020 04:46 pm ET
CORRECTION: Aditx Therapeutics, Inc. (Aditxt) Announces Closing of Initial Public Offering
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring,...
Jul 02, 2020 04:10 pm ET
Aditx Therapeutics, Inc. (Aditxt) Announces Closing of Initial Public Offering
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring,...
Jun 30, 2020 09:49 am ET
Aditx Therapeutics, Inc. (Aditxt) Announces Pricing of Initial Public Offering
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring, today...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.